Postes actifs de Laksh Aithani
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Charm Therapeutics Ltd.
 Charm Therapeutics Ltd. BiotechnologyHealth Technology Charm Therapeutics Ltd. is a British London-based company that is discovering and developing small molecule medicines using its proprietary 3D deep learning-enabled platform, Dragonfold. The company aims to create life-changing therapies for difficult-to-drug targets in cancer and other disease areas. Charm Therapeutics has raised $70 million to date and is supported by high-quality international investors, including Orbimed, F-Prime Capital, General Catalyst, Khosla Ventures, Bristol Myers Squibb, NVIDIA, and Grep-VC. The company was founded in 2021 by Laksh Aithani and David Baker, with Laksh Aithani serving as the CEO since then. | Directeur/Membre du Conseil | 24/09/2021 | - |
| Directeur Général | - | - | |
| Fondateur | 01/01/2021 | - |
Historique de carrière de Laksh Aithani
Statistiques
Internationale
| Royaume-Uni | 2 |
Opérationnelle
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
| Founder | 1 |
Sectorielle
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Charm Therapeutics Ltd.
Charm Therapeutics Ltd. BiotechnologyHealth Technology Charm Therapeutics Ltd. is a British London-based company that is discovering and developing small molecule medicines using its proprietary 3D deep learning-enabled platform, Dragonfold. The company aims to create life-changing therapies for difficult-to-drug targets in cancer and other disease areas. Charm Therapeutics has raised $70 million to date and is supported by high-quality international investors, including Orbimed, F-Prime Capital, General Catalyst, Khosla Ventures, Bristol Myers Squibb, NVIDIA, and Grep-VC. The company was founded in 2021 by Laksh Aithani and David Baker, with Laksh Aithani serving as the CEO since then. | Health Technology |
- Bourse
- Insiders
- Laksh Aithani
- Expérience
